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A Stable Cranial Neural Crest Cell Line from Mouse
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Cranial neural crest cells give rise to ectomesenchymal derivatives such as cranial bones, cartilage, smooth
muscle, dentin, as well as melanocytes, corneal endothelial cells, and neurons and glial cells of the peripheral
nervous system. Previous studies have suggested that although multipotent stem-like cells may exist during the
course of cranial neural crest development, they are transient, undergoing lineage restriction early in embryonic
development. We have developed culture conditions that allow cranial neural crest cells to be grown as mul-
tipotent stem-like cells. With these methods, we obtained 2 independent cell lines, O9-1 and i10-1, which were
derived from mass cultures of Wnt1-Cre; R26R-GFP-expressing cells. These cell lines can be propagated and
passaged indefinitely, and can differentiate into osteoblasts, chondrocytes, smooth muscle cells, and glial cells.
Whole-genome expression profiling of O9-1 cells revealed that this line stably expresses stem cell markers (CD44,
Sca-1, and Bmi1) and neural crest markers (AP-2a, Twist1, Sox9, Myc, Ets1, Dlx1, Dlx2, Crabp1, Epha2, and Itgb1).
O9-1 cells are capable of contributing to cranial mesenchymal (osteoblast and smooth muscle) neural crest fates
when injected into E13.5 mouse cranial tissue explants and chicken embryos. These results suggest that O9-1
cells represent multipotent mesenchymal cranial neural crest cells. The O9-1 cell line should serve as a useful tool
for investigating the molecular properties of differentiating cranial neural crest cells.
Introduction
Neural crest cells, a multipotent population of migra-tory cells, are of central importance to vertebrate or-
ganogenesis [1–3]. Neural crest cells are specified at the
border between neural and non-neural ectoderm during em-
bryogenesis. Subsequently, they undergo a transition from
epithelium to mesenchyme, and migrate, often, long dis-
tances. They ultimately differentiate into a variety of cell types
and contribute to many organs. Anomalies in neural crest
development underlie the pathophysiology of a variety of
human diseases [4,5], highlighting the importance of under-
standing of the molecular and cellular mechanisms that
govern neural crest development.
Depending on the site of origin along the anterior–posterior
axis of the embryo, neural crest cells fall into 3 populations,
cranial, cardiac, and trunk, each with a unique developmental
potential. The cranial neural crest, which originates in the
portion of the neural tube from the neural fold anterior to
rhombomere 6, has the ability to produce a greater diversity of
derivatives than other crest populations: Cranial neural crest
cells give rise to derivatives of the ectoderm, including pe-
ripheral nerves, as well as mesenchymal cell types, including
skeletal bone, cartilage, dentin, smooth muscle, and corneal
endothelial cells [6]. Trunk neural crest cells form a more
limited set of cell types, including peripheral nerves, mela-
nocytes, and the adrenalmedulla [6]. Cardiac neural crest cells
contribute to the smoothmuscle lining of the outflow tract [7].
Clonal culture experiments have shown that trunk neural
crest cells include a population of self-renewing multipotent
stem cells [8]. Whether other neural crest populations also
contain such populations is not clear. In the case of cranial
neural crest cells, individual cells derived from quail em-
bryos have been shown to be multipotent [9,10]. However,
these cells have not been maintained as stable, long-term cell
lines; consequently, the question of whether these cells have
the ability to self-renew has not been addressed.
One of our main long-term goals is to test the hypothesis
that the cranial neural crest contains a population of self-
renewing stem cells. For this purpose, we have sought to de-
velop clonal culture conditions that will allow us to evaluate
the differentiation potential of individual cranial neural crest
cell clones. As a first step toward this goal, we have identified
conditions that enable murine cranial neural crest cells to
be cultured en masse, and conditions in which such mass-
cultured cranial neural crest cells to bemaintained in vitro in a
multipotent state. We have isolated 2 multipotent non-clonal
cell lines, one of whichwe have characterized extensively. The
cell line designated O9-1 has the capacity to differentiate
in vitro into osteoblasts, a defining characteristic of cranial
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neural crest cells, aswell as chondrocytes, smoothmuscle, and
glial cells. In vivo, O9-1 cells can contribute to cranial mes-
enchymal derivatives, including osteoblasts and smooth
muscle cells. The O9-1 cell line can be passaged extensively,
stably maintaining its multipotency. Whole-genome expres-
sion profiling suggests that the O9-1 cell line has characteris-
tics of both cranial neural crest and stem cells. We believe that
the O9-1 cell line will be a powerful asset in the investigation
of the molecular properties of cranial neural crest cells.
Materials and Methods
Culture medium
The basal medium for neural crest culture was prepared as
following. The Dulbecco’s modified Eagle’s medium
(DMEM), 15% fetal bovine serum (FBS), 0.1mM minimum
essential medium (MEM) non-essential amino acids, 1mM
sodium pyruvate, 55mM b-mercaptoethanol, 100U/mL
penicillin, 100mg/mL streptomycin, and 2mM L-glutamine,
was conditioned by STO feeder cells (ATCC) for an over-
night. The medium was filtered (0.22-mm pore size) and
supplemented with 25 ng/mL basic fibroblast growth factor
(bFGF; R&D Systems) and 1,000U/mL leukemia inhibitory
factor (LIF; Millipore).
Neural crest cell culture
Cranial neural crest cells labeled with Wnt1-Cre; R26R-GFP
[7,11,12] were obtained from E8.5 mouse embryos. Cranial
tissues above the level of the second pharyngeal arch were
dissected in DMEM supplemented with 10% fetal calf serum
(FCS), washed by phosphate-buffered saline (PBS), and then
incubated in 0.025% trypsin, 1mg/mL collagenase in 0.25mM
EDTA for 5min at 37C. Cells were dissociated by gentle pi-
petting and neutralized in DMEM with 10% FCS. Then, cells
were initially expanded on a Matrigel- (Becton Dickinson)
coated plate with the basal medium at 37C, 5.5% CO2. Con-
fluent culture was subjected to fluorescence-activated cell
sorting (FACS) by theMoFlo cytometer (cytomation), andGFP-
positive cells were seeded on a Matrigel-coated plate with the
basal medium. Cells were seeded at 10,000–15,000 cells/cm2,
and it took 3–4 days before they reach to the confluence. For
passaging, cells were rinsed with PBS twice and treated with
0.05% trypsin in 0.5mM EDTA at 37C for 3min. Cells were
neutralized in 10% FCS in DMEM and gently pipetted. Cells
were maintained in logarithmic growth, and as a standard
procedure, culture was diluted 2 to 3 times with aimed seeding
density*0.8–1.0· 105 cells/cm2. Under this condition, cranial
neural crest cells can be passaged for an extended time.
Cell differentiation
To induce differentiation, cells were cultured in the
following conditions: osteogenic differentiation medium [a-
MEM, 10% FBS, 100U/mL penicillin, 100mg/mL strepto-
mycin, 0.1 mM dexamethasone, 10mM b-glycerophosphate,
50 mg/mL ascorbic acid, and 100 ng/mL BMP2 (gift from
B. Frenkel)], smooth muscle differentiation medium (DMEM,
10% FBS, 100U/mL penicillin, and 100 mg/mL streptomy-
cin), and glial differentiation medium [DMEM/F12, 1· B27
(Invitrogen), 2mM L-glutamine, 50 ng/mL BMP2, 50 ng/mL
LIF (Millipore), 1% heat-inactivated FBS, 100U/mL penicil-
lin, and 100 mg/mL streptomycin]. For chondrogenic differ-
entiation, monolayer culture was initially treated with the
osteogenic medium for 3 days. Then, cells were trypsinized
and cultured as a micromass format in a chondrogenic
medium [a-MEM, 5% FCS, 1% ITS (BD Biosciences), 100U/
mL penicillin, 100 mg/mL streptomycin, 10 ng/mL TGF-b3
(R&D systems), 50mg/mL ascorbic acid, 10 ng/mL BMP2,
0.1 mM dexamethasone, and 1mM sodium pyruvate] for
additional 7 days.
Osteogenic and chondrogenic differentiation was assessed
by Alizarin red, alkaline phosphatase (ALP), and Alcian
blue staining [13]. To detect smooth muscle and glial cell
differentiation, immunofluorescence was performed with
anti-a-smooth muscle actin (aSMA; Sigma), anti-Fabp7, and
anti-GFAP (Millipore) antibodies.
Primers
Primers used in this study are shown in Supplementary
Data S1 (Supplementary Data are available online at
www.liebertpub.com/scd).
FACS analysis
O9-1 and i10-1 cells were immunophenotyped by
phycoerythrin-conjugated anti-CD44 and allophycocyanin-
conjugated anti-Sca-1 antibody, as well as isotype controls
purchased from eBioscience. The cells were incubated with
1/200 diluted antibodies at 4C for 30min and washed.
Analysis was performed by MoFlo (Cytomation).
Microarray analysis
RNA samples were extracted from a triplicated culture of
O9-1 cells grown in the basal medium (passage13) and
purified using a PicoPure RNA Isolation Kit (Arcturus).
Genome-wide RNA expression profile of O9-1 cells was
conducted using Illumina MouseRef-8 V2.0 Expression
BeadChip (Illumina). The raw intensity data were imported
into Illumina GenomeStudio v3 and subsequently exported to
Partek Genomic Suite v6 (PGS; Partek, Inc.) using a plug-in
script provided by Partek without normalization and back-
ground correction. As controls, GEO data sets generated from
E8.25 mouse ectoderm ([14], GSE13040) and E12.5 mouse
dorsal root ganglia (DRG) ([15], GSE24730) were directly im-
ported into PGS. All data sets were combined and then sub-
jected to log transformation and quantile normalization [16].
To detect differentially expressed genes (DEG) in O9-1 cell line
versus the control tissues, a one-way ANOVA was performed
using the gene expression workflow in PGS. Lists of the most
significant DEG were generated with stringent criteria: a false
discovery rate corrected P< 0.05 using the Benjamini-Hoch-
berg step-up procedure [17] to account for multiple testing
and the difference in mean gene transcript level was at least 2-
fold in either direction. We used the same approach to identify
DEG of the human trunk neural crest cell lines ([18],
GSE14340) versus human Schwann cells (GSE4030).
Analysis of developmental potency of cultured
neural crest cells by microinjection into mouse
and chick embryos
To assess the ability of cultured neural crest cells to
undergo osteogenic and smooth muscle differentiation, we
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cultured the upper half of E13.5 mouse heads as described
[19] with some modifications. In typical experiments,
*3.5 · 106 of O9-1 cells were resuspended in 100 mL of 10%
FBS in DMEM. O9-1 cells (P18) were injected with a mouth
pipette into area adjacent to the frontal bone primordium.
Explants were cultured in the BGjb medium for 3 days (see
Fig. 4). In the case of the smooth muscle lineage, O9-1 cells
were prepared as described above and injected into the
frontonasal prominence of the HH stage17 chicken embryos
by following to [20]. Embryos were cultured for 24 h and
harvested. Both mouse organ explants and chicken embryos
were fixed in 4% paraformaldehyde and cryosectioned.
In the case of mouse explants, injected cells were visualized
by means of immunohistochemistry with anti-GFP antibody
(Invitrogen) or immunofluorescence with the TSA tyramide
system (PerkinElmer) due to a high level of host auto-
fluorescence. Osteogenic differentiation was assessed by
ALP staining [13], and smooth muscle differentiation was
assessed by immunofluorescence with anti-aSMA anti-
body, followed by anti-mouse IgG Rhodamine (Invitrogen)
staining.
CD44 immunofluorescence
Cranial tissues of E8.5 through E10.5 Wnt1-Cre; R26R-GFP
mouse embryo were fixed in 4% paraformaldehyde and
cryosectioned. Tissues were stained with anti-CD44 antibody
(eBioscience) and visualized by anti-Rat IgG Alexa568 (In-
vitrogen).
Results
Mass-cultured cranial neural crest cells sustain
stem-like potency
We isolated cranial neural crest cells from E8.5 mouse
embryos by means of FACS (Fig. 1). The cells were labeled
with aWnt1-Cre; R26R-GFP reporter. We found that by using
a combination of Matrigel-coated culture dishes and a me-
dium conditioned by STO feeder cells and supplemented
with bFGF and LIF, we were able to obtain sustained growth
of mouse cranial neural crest. bFGF is essential for adequate
growth of these cells. We have thus far isolated 2 indepen-
dent mass culture lines, O9-1 and i10-1. When cultured with
various differentiation media, both of these cell lines were
capable of differentiating into several different cell types,
including osteoblasts, chondrocytes, smooth muscle cells,
and glial cells (Fig. 1; data not shown). Neither cell line
showed a neuronal phenotype when exposed to conditions
that were capable of causing neuronal differentiation [21],
and melanocyte conditions were not tested.
By performing reverse transcriptase polymerase chain re-
action (RT-PCR) analysis at different passages, we found that
both cell lines continually express the neural crest markers,AP-
2a, Twist1, and Snail1, and the stem cell markers, nestin, CD44,
and Sca-1 (Figs. 1 and 2; data not shown). Flow cytometry
analysis showed that more than 84% of O9-1 cells are positive
for both CD44 and Sca-1. In the case of i10-1, the CD44-Sca1
double-positive fraction was more than 97% (Fig. 1). O9-1 cells
stably maintained their multipotency as well as the expression
of key markers through passages P17 and P22 (see Fig. 2).
Findings of sustainable differentiation potential, multi-
potency, and expression of neural crest markers suggest that
these mass-cultured cells have key properties expected of
cranial neural crest cells. Since O9-1 and i10-1 cell lines had
equivalent marker gene expression profiles, proliferation
ratios, and differentiation potential (Figs. 1 and 2; data not
shown), we chose to focus on the O9-1 cell line in subsequent
analyses.
Whole-genome expression profiling revealed
that the O9-1 cell line exhibits characteristics
of mesenchymal cranial neural crest
Initial marker analysis with RT-PCR suggested the O9-1
cell line has features of neural crest cells as well as mesen-
chymal and neural stem cells. To further test the hypothesis
that the O9-1 cell line represents a native state of developing
cranial neural crest cells, we carried out whole-genome ex-
pression analysis by means of Illumina microarrays (Illumi-
na). To detect DEG, E8.25 mouse ectoderm ([14] GSE13040)
and E12.5 mouse DRG ([15] GSE24730) were used as con-
trols. E8.25 ectoderm should contain few or no neural crest
cells, whereas E12.5 DRG is formed entirely from a trunk
neural crest population differentiating into neuronal, glial,
and smooth muscle cells. Thus, comparison of O9-1 cell line
with E8.25 ectoderm should highlight the difference between
neural crest and non-neural crest cells, whereas comparison
with E12.5 DRG should illuminate differences of undiffer-
entiated versus differentiated neural crest, as well as cranial
versus trunk neural crest cells.
Markers of neural crest were increased significantly in the
O9-1 cell line relative to both ectoderm and the DRG cell line
(fold change > 2; P< 0.05): these include Tcfap2a (AP-2a),
Twist1, Sox9, Myc, Ets1, Dlx1, Dlx2, Crabp1, Epha2, and Itgb1.
Additional neural crest markers (a total of 25) also showed
higher levels of expression (Table 1 and Supplementary Data
S2). Snail1 and Msx1 were increased in the O9-1 cell line in
comparison with E12.5 DRG cell line, but not in comparison
with ectoderm.
We did not detect an increase in the expression of Foxd3 or
Sox10 in O9-1 cells, as would be expected of cells capable of
ectodermal fates. We noted a higher level of Sox9 expression
and a lower level of Sox10 expression, characteristics of
cranial neural crest cells that have migrated into the pha-
ryngeal arches and become committed to mesenchymal fates
[22–24]. These data suggest that the O9-1 cell line models the
ectomesenchymal cells in the cranial region.
Expression profiling of O9-1 cells showed some similar-
ity to neural crest stem cells found in the enteric nerve
(enNCSCs) [25,26]. The O9-1 cell line expresses Bmi1, Arpc1b,
CD9, and Cyba, which are highly expressed in enNCSCs.
These results suggest that the O9-1 cell line may represent an
undifferentiated subpopulation of cranial neural crest. In
agreement with this, additional stem cell markers, including
CD44, CD47, Ly6a (Sca-1), and Klf4, were highly expressed in
O9-1 cells. Markers that represent differentiating neural crest
showed a lower level of expression [Tkrb and Tkrc (neuronal
cell differentiation); Mbp, Plp and Gap43 (Schwann cell dif-
ferentiation); and Col2a1 (chondrogenic differentiation)]. A
downregulation of differentiation markers was more obvious
in comparison with DRG. Such markers include neuronal
(Neurod1, Neurod4, Nefm, and Prph1), glial (Fabp7 and Slc1a3),
and smooth muscle (aSMA) lineage markers (see Table 1).
These results suggest that the cell line O9-1 exhibits
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properties expected of cranial neural crest cells committed to
a multipotent ectomesenchymal lineage.
Thomas and colleagues [18] established stable trunk neu-
ral crest cell lines from the human fetus (trunk hNCC). These
cells can be passaged multiple times in vitro during which
time they continuously express neural crest markers [18]. The
culture also contains cells that express smooth muscle, neu-
ronal, or glial cell markers [18], suggesting that these cells
differentiate into the derivatives of trunk neural crest. We
first determined DEG in the human trunk neural crest cell
lines (GSE14340) versus human Schwann cells (GSE4030),
and then asked whether these results are relevant to the DEG
FIG. 1. Sustainable stem-like potency of cranial neural crest cell lines. (A) Overall protocol. Cranial neural crest cells labeled
with Wnt1-Cre; R26R-GFP were obtained from E8.5 mouse embryos. Dissociated cells were initially expanded in vitro for 3
days and sorted by fluorescence-activated cell sorting (FACS) (arrowhead). Sorted cells were cultured on Matrigel-coated
plates with a basal medium. Under this condition, cranial neural crest cells can be passaged for an extended time. Two
independent mass culture lines were established (O9-1 and i10-1). The morphology (B) and growth ratio (C) of mass culture
O9-1 cells. Doubling time is *27 h. (D–G) Long-term cultured mass cranial neural crest differentiates into multiple cell
lineages. Shown is the line O9-1, which is capable of differentiating into osteoblasts (D), chondrocytes (E), smooth muscle cells
(F), and glial cells (G). (H) These cells express GFP as a transgenic reporter (shown is line O9-1). (I) Marker gene expression
analysis by RT-PCR. Both lines (O9-1/passage11 and i10-1/passage10) express AP-2a, Twist1, and Snail1 (neural crest
markers). They also express nestin, CD44, and Sca-1 (stem cell markers). ( J) Flow cytometry analysis of the O9-1 cell line for
CD44 and Sca-1 expression. More than 84.17% of O9-1 cells are double positive for CD44 and Sca-1 (right). Isotype antibodies
(negative control; left and middle) show no staining. (K) Cell growth of the O9-1 and i10-1 lines is highly dependent on the
basic fibroblast growth factor (bFGF) supplement. Error bars are standard deviations derived from 3 independent experi-
ments. Scale bars: in (B, D–F, H) 200mm; in (G) 100mm. RT-PCR, reverse transcriptase-polymerase chain reaction.
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in the O9-1 and mouse DRG (see above). Intriguingly, these
comparisons showed certain similarities in the expression of
genes involved in neural crest development. Some neural
crest markers were increased (Twist1, Myc, Snail1, Sox9,
Epha2, Rarg, Rac1, and Cald1), while others were decreased or
unchanged [Sox10, Ngfr ( p75), and Ednrb] (Supplementary
Data S3). In addition, neuronal (Neurod4 and Nefm) as well as
glial differentiation markers (Mbp, GAP43, and Fabp7) were
both decreased (Supplementary Data S3). These results
suggest that the O9-1 and trunk hNCC cell lines both retain
certain properties of neural crest and negatively regulate
neuronal lineage differentiation. Differences between the O9-
1 and trunk hNCC cell lines were also evident. For example,
some of the key markers expressed in the O9-1 cell line were
not detected in the trunk hNCC lines (Crabp1, Ets1, Dlx1,
Dlx2, CD44, Bmi1, Barx1, Prrx1, Arpc1b, CD9, and Cyba, Table
1, not shown). In addition, Hox cluster genes were signifi-
cantly decreased in O9-1 cells (total of 21 Hox genes),
whereas they were increased in the trunk hNCC lines (total
of 19 Hox genes) (Supplementary Data S2 and S3, data not
shown). The observed differences between O9-1 and trunk
hNCC lines in the expression of Hox genes were consistent
with the expected differences between cranial versus trunk
neural crest cells [6]. The trunk hNCC lines were reported to
have a spontaneous expression of the smooth muscle marker,
aSMA [18]. Our analysis also detected an increased level of
aSMA expression, together with other smooth muscle
markers TAGLN (SM22) and CNN1 (Calponin 1). In contrast,
O9-1 cells exhibit reduced expression of aSMA (see above)
and no change in Tagln and Cnn1 (not shown). Thus, it seems
that spontaneous differentiation of smooth muscle is more
efficiently repressed in the O9-1 cell line than in the human
trunk neural crest cell line.
The osteogenic differentiation of O9-1 cells can be
controlled precisely by extrinsic conditions
Osteogenic potential distinguishes cranial neural crest
from other neural crest populations [6]. We therefore inves-
tigated the osteogenic differentiation of O9-1 cells in more
detail. We placed cells in osteogenic conditions and moni-
tored cellular morphology and the expression of various
FIG. 2. O9-1 cells exhibit sustainable multipotency and expression of marker genes for neural crest and stem cells. (A–L)
Differentiation ability of the O9-1 cell line in its earlier (P17) and later (P22) passage points. O9-1 cells have an identical
morphology at those passage points (A, B) and are capable of differentiating into osteogenic (C, D), chondrogenic (E, F),
smooth muscle (G, H), and glial lineages (I–L). To evaluate cell differentiation, Alizarin red, Alcian blue, immunofluorescence
of aSMA, Fabp7, and GFAP were performed, respectively. (M) RT-PCR results show continuous expression of neural crest
and stem cell markers. Scale bars: in (A, E, G) 200 mm for (A, B, E–H); in (C) 2mm for (C, D); in (L) 100 mm for (I–L).
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Table 1. O9-1 Illumina Analysis
Symbol Fold-change P value Fold-change P value Annotation
O9-1 up vs. DRG O9-1 up vs. ectoderm
Crabp1 28.8 6.00E-07 5.03 4.37E-05 Neural crest
Dlx1 17.6 1.88E-05 25.6 9.27E-06 Neural crest
Dlx2 7.39 3.16E-06 7.09 3.58E-06 Neural crest
Epha2 4.89 2.74E-07 4.02 6.00E-07 Neural crest
Ets1 2.73 1.66E-03 4.26 2.35E-04 Neural crest
Itgb1 2.63 6.65E-05 6.03 1.82E-06 Neural crest
Myc 2.34 2.27E-08 2.49 1.50E-08 Neural crest
Sox9 6.48 7.18E-07 2.49 4.72E-05 Neural crest
Tcfap2a (AP-2a) 3.66 1.04E-04 3.72 9.60E-05 Neural crest
Twist1 4.81 6.22E-06 6.80 1.93E-06 Neural crest
Cald1 2.09 2.01E-05 2.21 1.32E-05 Neural crest migration
Cfl1 2.74 2.06E-04 2.69 2.29E-04 Neural crest migration
Rac1 4.28 2.88E-06 3.03 1.41E-05 Neural crest migration,
post-migratory cell proliferation
Barx1 6.23 1.27E-08 5.70 1.71E-08 Pharyngeal arch mesenchyme
Prrx1 (Prx1) 18.2 9.19E-08 32.6 3.08E-08 Facial mesenchyme
Rarg 5.31 2.01E-07 4.81 2.88E-07 Pharyngeal arches, periocular
mesenchyme, cranial ganglia
Gli3 2.71 2.84E-06 2.22 1.04E-05 Palatogenesis
Runx2 2.54 2.97E-07 2.33 5.30E-07 Osteogenic differentiation,
multipotent stem-like cell
Spp1 53.7 1.60E-06 106 6.25E-07 Osteogenic differentiation
Col1a1 6.25 7.36E-08 17.5 5.10E-09 Osteogenic differentiation
Arpc1b 12.2 1.97E-09 17.8 8.41E-10 Enteric nerve neural crest stem cell
Cd9 6.64 7.65E-06 12.9 1.31E-06 Enteric nerve neural crest stem cell
Cyba 5.44 3.99E-05 4.49 7.93E-05 Enteric nerve neural crest stem cell
Bmi1 4.59 1.10E-06 5.79 4.77E-07 Enteric nerve neural crest stem cell
Cd44 19.2 3.28E-08 14.2 6.17E-08 Stem cell
Cd47 2.08 1.10E-03 4.45 2.13E-05 Stem cell
Klf4 6.19 3.09E-08 7.47 1.72E-08 Stem cell
Ly6a (Sca-1) 7.99 5.35E-08 7.18 7.31E-08 Stem cell
O9-1 down vs. DRG O9-1 down vs. ectoderm
Cxcr4 - 2.75 4.54E-05 - 4.39 5.05E-06 Neural crest
Id2 - 5.70 4.43E-06 - 9.67 9.27E-07 Neural crest, neuronal differentiation
Meis1 - 3.11 1.71E-04 - 6.56 9.52E-06 Neural crest
Ngfr (p75) - 29.2 2.74E-07 - 2.26 9.47E-04 Neural crest, neuronal differentiation,
trunk neural crest stem cell
Robo1 - 7.02 2.48E-06 - 7.85 1.79E-06 Neural crest, axon guidance
Tcfap2b - 5.37 7.71E-03 - 4.98 9.47E-03 Neural crest
Zic1 - 15.5 4.02E-05 - 2.43 1.37E-02 Neural crest, neuronal differentiation
Zic2 - 2.27 6.85E-03 - 2.99 1.66E-03 Neural crest, neuronal differentiation
Reln (reelin) - 3.92 1.25E-07 - 6.12 2.32E-08 Neuronal development
Ntrk2 (Tkrb) - 4.11 2.82E-05 - 2.52 3.12E-04 Neuronal differentiation
Ntrk3 (Tkrc) - 3.88 4.77E-05 - 2.92 1.79E-04 Neuronal differentiation
Mbp - 2.49 3.83E-04 - 3.01 1.35E-04 Schwann cell differentiation
Plp - 30.7 4.47E-07 - 5.95 2.08E-05 Proteolipid protein (myelin) 1
Gap43 - 61.3 6.11E-09 - 4.26 3.06E-06 Neural crest migration, Schwann cell
differentiation, neuroblastoma
Vldlr - 3.92 3.54E-06 - 6.34 5.95E-07 Neuronal differentiation
Col2a1 - 4.88 1.87E-04 - 3.31 8.63E-04 Chondrogenic differentiation
Ckb - 41.4 2.30E-08 - 4.24 6.32E-06 Enteric nerve neural crest stem cell
Ednrb - 68.2 2.82E-07 - 2.87 8.15E-04 Enteric nerve neural crest stem cell
Rbp1 - 6.93 1.86E-05 - 6.60 2.15E-05 Enteric nerve neural crest stem cell
Bmp4 - 3.72 4.52E-05 - 5.07 1.33E-05 Osteogenic, chondrogenic,
smooth muscle differentiation
Bmp7 - 2.97 1.38E-05 - 2.57 3.14E-05 Osteogenic differentiation
O9-1 up vs. DRG O9-1 down vs. ectoderm
Hk2 3.00 1.36E-03 - 3.73 5.22E-04 Neural crest
Msh6 2.06 2.40E-03 - 2.11 2.05E-03 Neural crest
Msx1 4.63 1.22E-06 - 2.03 1.13E-04 Neural crest
(continued)
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osteogenic markers at different time points (day 0, 1, 3, 5, 7,
and 10).
The morphology of O9-1 cells began changing on the second
day (day 1). The cells lost their fibroblastic appearance and
became more cuboidal (Fig. 3B). The cells formed aggregates by
day 5 (Fig. 3D) and nodule-like structures by day 10 (Fig. 3F).
Initially, the expression of osteogenic markers [ALP and
osteocalcin (OCL)], as well as the osteogenic regulator, Msx2
[27], was undetectable. Within 1 day, the expression of these
markers was readily apparent (Fig. 3). Also, Runx2 and os-
teopontin (Spp1) expression rose from barely detectable to
prominent during the course of the experiment. That O9-1
cells do not differentiate spontaneously along an osteogenic
pathway, but instead require an osteogenic medium, for such
differentiation shows that the induction of osteogenic dif-
ferentiation of O9-1 cells is governed by extrinsic conditions,
and occurs in a controlled manner.
O9-1 cells assume mesenchymal cranial neural
crest fates when injected into embryos
We made use of a mouse organ culture system as well as
chicken in ovo culture system to ask whether the O9-1 cell
line can integrate into differentiating cranial structures de-
rived from cranial neural crest. Undifferentiated cells prop-
agated in the basal medium were injected into E13.5 mouse
periorbital prominences, which were then cultured in the
BGjb medium for 3 days. We also injected O9-1 cells into the
frontonasal prominence of chicken embryos and cultured
them for 24 h (Fig. 4). We examined mesenchymal neural
crest derivatives for contributions of O9-1 cells. We found
that injected O9-1 cells differentiated into osteogenic and
smooth muscle lineage cells, which are mesenchymal deriv-
atives (Fig. 4). Of 14 injected mouse explants, over 25%
showed integration into the osteogenic lineage, and over 20%
showed differentiation into smooth muscle. In surviving
chicken embryos, 1 of 3 showed smooth muscle differentia-
tion. These results provide evidence that the O9-1 cell line
closely approximates undifferentiated ectomesenchymal cells
derived from the cranial neural crest.
CD44 marks migratory and postmigratory cranial
neural crest cells in mouse
As noted above, O9-1 cells express the stem cell marker,
CD44. This molecule is expressed in migratory and post-
migratory cranial neural crest cells in Xenopus [28] and mi-
gratory cranial neural crest cells in chicken [29]. In Xenopus,
downregulation of CD44 by morpholino antisense resulted
in delayed migration of cranial neural crest, suggesting that
CD44 has an essential role in neural crest migration [28].
However, the expression pattern of CD44 in murine neural
crest has not been described in detail. Thus, to verify the
utility of CD44 as a marker of neural crest cells in the mouse,
we assessed its expression in mouse embryos at E8.5–E10.5.
We found that CD44 is expressed in cranial neural crest cells
in both the migratory and post-migratory phases from E8.75
through E9.5 (Fig. 5, data not shown), supporting the hy-
pothesis that the O9-1 cell line represents a population of
cranial neural crest in the migratory through post-migratory
stages. At E8.75, virtually no positive cells were found in the
early phase of migration (not shown), whereas a majority of
the late migratory or post-migratory cells were positive (Fig.
5). Expression of CD44 in cranial neural crest was markedly
reduced by E10.5 (not shown).
Discussion
Here, we describe stable cell lines that exhibit properties of
an undifferentiated mesenchymal population of cranial
neural crest cells. One such cell line, O9-1, is capable of
differentiating into 4 cell types, including osteoblasts, chon-
drocytes, smooth muscle cells, and glial cells. O9-1 cells ex-
press neural crest markers, as well as stem cell markers. They
Table 1. (Continued)
Symbol Fold-change P value Fold-change P value Annotation
O9-1 up vs. DRG
Myo10 2.9 1.40E-05 Neural crest
Snail (Snail1) 3.03 2.28E-04 Neural crest
O9-1 down vs. DRG
Acta1 (aSMA) - 2.41 3.70E-03 Smooth muscle differentiation
Ednra - 2.75 2.12E-03 Pharyngeal arch development
Nefm - 66.1 8.80E-08 Neuronal differentiation
Neurod1 - 3.65 2.69E-05 Neuronal differentiation
Neurod4 - 7.78 8.22E-06 Neuronal differentiation
Sostdc1 - 5.19 1.47E-02 Tooth development
Fabp7 - 5.92 1.53E-05 Glial differentiation
Myt1 - 35.9 2.69E-08 Myelin transcription factor 1
Mapt - 46.2 1.00E-06 Neuron-specific protein
Prph1 - 32.0 7.04E-06 Peripheral neurons
(Peripherin)
Slc1a3 - 5.96 4.30E-06 Glial differentiation
Smad1 - 2.79 6.69E-06 TGF/BMP signal effector
Smad5 - 2.32 8.20E-06 TGF/BMP signal effector
O9-1 down vs. ectoderm
Sp7 (Osterix) - 2.85 8.54E-08 Osteogenic differentiation
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also express genes involved in craniofacial development, and
are able to integrate into differentiating bone and smooth
muscle in E13.5 mouse embryos, as well as smooth muscle in
chicken embryos. We suggest that these cells will provide a
tool for investigating the molecular properties of differenti-
ating neural crest cells.
A major limitation in the investigation of the molecular
properties of cranial neural crest cells is the difficulty of
obtaining sufficient quantities of cells for biochemical stud-
ies. One approach that would overcome this limitation is a
system for culturing cranial neural crest in such a way as to
provide a large quantity of homogeneous cells that represent
the native state of cranial neural crest cells. Although cell
lines derived from trunk neural crest are available (trunk
hNCC [N1–N5] [18], MONC-1 [30], and JoMa1.3 [31]), there
is no generally accepted sustainable cell culture model for
cranial neural crest.
There is evidence that early-stage cranial neural crest cells
have stem-like properties. Calloni and colleagues [9] isolated
single neural crest cells from quail embryos and showed that
they can differentiate into 6 cell-types, in vitro. Because these
cells were not a stable cell line and thus could not be main-
tained in culture, it was not possible to determine whether
they had the ability to self-renew. To address this issue,
Trentin and colleagues established stable cranial neural crest
cell lines with the ability to self-renew [32]. These cells
showed a limited ability to differentiate, functioning as bi-
potent progenitors [32]. The question of whether a popula-
tion of self-renewing neural crest stem cells exists in vivo
therefore remains open. Our work, by identifying conditions
that can maintain cranial neural crest cells in a multipotent
state, suggests an approach to the clonal culture of cranial
neural crest, and thus a direct test of hypothesis that a
population of multipotent cranial neural crest cells exists
in vivo. We note that although we have sought conditions
that maintain a normal karyotype during cell expansion, we
were unsuccessful to date. Thus, a form of transformation
may be required to maintain sustainable growth of cranial
neural crest in vitro.
Several neural crest markers were either not detectable in
O9-1 cells or were reduced in O9-1 cells relative to DRG and
ectoderm; these include Foxd3, Tcfap2b, Sox10, Ngfr ( p75),
Zic1, Zic2, Id2, and Robo1 (see Table 1). Some of these
markers are known to be expressed in neural crest precursors
in the neural plate as well as in differentiating neuronal and
glial cells [33–37]. The reduced expression of these markers
may indicate that O9-1 cells have a non-neural character.
Indeed, our finding of increased expression of Sox9 and no
change in expression of Sox10 relative to E8.25 ectoderm
and E12.5 DRG is consistent with the view that O9-1
cells resemble undifferentiated mesenchymal cranial neural
crest cells.
Our data suggest that there may be a difference in the
potency of O9-1 cells in vitro versus in vivo. The O9-1
cell line can differentiate in vitro into both mesenchymal
(osteogenic, chondrogenic, and smooth muscle) and non-
FIG. 3. Osteogenic differentiation of O9-1 cells. (A–F) Treatment of O9-1 cells with an osteogenic differentiation medium
resulted in a dramatic morphological change from a fibroblast-like appearance to a cuboidal shape (panel A–C), and tight
adhesion between the cells. By day 5 (D), the cells had condensed. By day 10 (E, F), nodule-like structures had formed (F,
arrowheads). Such structures are typical of osteogenic tissues. All of those images were taken under the bright field. (G) RT-
PCR was performed to see the level of mRNA expression of various osteogenic markers. On day 0, nearly undetectable level
of alkaline phosphatase (ALP), osteocalcin (OCL), and Msx2 mRNA were seen. However, shortly after osteogenic medium
treatment has begun (day 1), expression of these markers became significantly high. Runx2 and Spp1 (osteopontin) mRNA
were expressed at low level in day 0. It was gradually increased on later time points. These data indicate that tightly
controlled osteogenic differentiation takes place in the O9-1 cell line. nd, bone nodule. Scale bar: 200 mm. Color images
available online at www.liebertpub.com/scd
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FIG. 4. Ectomesenchymal potential of the O9-1 cells in differentiating mouse organ explants and chicken embryo. To verify
the differentiation ability of the O9-1 cell line in the cranial tissues, we performed microinjection experiments with an in vitro
organ culture model. (A) Diagrams illustrate the strategy of O9-1 microinjection into E13.5 mouse upper cranial explants. We
cultured these explants for 3 days in the BGjb medium. Injected cells were traced in histological sections by means of GFP
labeling and staining with the osteogenic differentiation marker, ALP, and the smooth muscle differentiation marker, a-
smooth muscle actin (aSMA). (B–G) In the upper cranial explants, O9-1 cells were found among differentiating osteogenic
cells in the frontal bone primordium. Arrows indicate that the O9-1 cells positive for both GFP (B, E) and ALP (C, F). (E–G)
show the area demarcated in panels (B–D). (H–K) A subpopulation of O9-1 cells injected into the upper cranial explants
expresses aSMA. Arrows indicate the O9-1 cells positive for both GFP (I) and aSMA ( J). (L) We also microinjected O9-1 cells
into the frontonasal prominence of HH stage17 chicken embryos. After injection, embryos were cultured in ovo for 24 h, and
injected cells were traced histologically by GFP and staining with the smooth muscle differentiation marker, aSMA. (M–P)
O9-1 cells can differentiate into the smooth muscle cells in chick. Arrows indicate the O9-1 cells positive for both GFP (green)
(N) and aSMA (red; Rhodamine) (O). In some area, smooth muscle differentiation of the host embryo (arrowhead inO) and the
O9-1 cell line appears to be synchronized. These lineage-tracing experiments revealed that O9-1 cells are capable of differ-
entiating into mesenchymal lineages. fbp, frontal bone primordium; bh, brain hemisphere; nt, neural tube. Scale bars: in (D,
G, P) 100 mm for (B–D), (E–G), and (M–P); in (K), 50mm for (H–K).
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mesenchymal (glial) lineages. In contrast, we have thus far
only been able to demonstrate osteogenic and smooth muscle
fates, in vivo. This difference may be technical and caused,
for example, by our limited ability to inject O9-1 cells into
embryos at the right time and place to observe non-
mesenchymal fates. Alternatively, it may indicate that, as the
marker studies suggest, O9-1 cells model the mesenchymal
neural crest lineages more closely than the non-mesenchymal
ones.
We found that CD44 is expressed in a subset of migratory
cranial neural crest cells as well as postmigratory neural crest
in E8.75 mouse embryos as well as in O9-1 cells (Figs. 1 and
5). Chung and colleagues have also found that CD44 is ex-
pressed in stem-like cells derived from the postmigratory
cranial neural crest in mouse mandibular tissues [38]. These
findings are consistent with the results of Menendez and
colleagues [39], who showed that CD44 is exclusively ex-
pressed in neural crest cells restricted to a mesenchymal fate
in human.
Microarray analysis showed that O9-1 cells express the
osteogenic markers, Runx2, Spp1 (osteopontin), and Col1a1
(type I collagen). On the other hand, several additional oste-
ogenic genes, including Sp7 (Osterix), and elements of the
Bmp signaling pathway were decreased relative to either
DRG or ectoderm (see Table 1). Despite the expression of
osteogenic markers, the O9-1 cell line does not differentiate
spontaneously into osteogenic cells, but instead is highly
dependent on the osteogenic medium for osteogenic differ-
entiation (Fig. 3). It is interesting to note that Runx2 ex-
pression is linked to multipotent stem-like characteristics of
cranial neural crest in the quail [9]. Similarly, osteopontin has
roles in settings outside osteogenic differentiation, control-
ling tumor progression and metastasis [40]. Thus, expression
of Runx2 and osteopontin may be an indication of the stem
cell character and migratory properties of O9-1 cells.
Migratory cranial neural crest cells are distinguished by
the expression Cald1 and Cfl1 [41,42]. Postmigratory neural
crest cells express their own unique set of markers, including
Barx1, Prrx1 (Prx1), and Rarg [43–45]. Rac1 functions in both
the migratory and postmigratory neural crest [46–48]. Our
array analysis revealed that O9-1 cells express genes typical
of each category, including the migratory neural crest
markers and the postmigratory markers. These results sug-
gest that the O9-1 cell line has some properties of both phases
of neural crest cell development.
Previous studies showed enhanced chondrogenic and glial
differentiation of cultured mouse cranial neural crest by
bFGF via activation of the Notch-signaling pathway [49,50].
In our culture conditions, bFGF functions together with LIF
to promote the sustainable expansion of the culture while
maintaining the cells in an undifferentiated state. bFGF
controls the balance between proliferation and differentiation
of mesenchymal cranial neural crest in vitro [51]. We found
that, indeed, O9-1 cells have significantly reduced expression
of Notch receptors (Supplementary Data S2, data not
shown). Thus, bFGF may act differently depending on the
context of the cell culture condition, including supplemented
cofactors.
Finally, we found recently that osteogenic progenitors
derived from O9-1 cells exhibit Bmp2 responsiveness similar
to the frontal bone primordium of E12.5 mouse embryos
( Jingjing Sun, M.Ishii, and R.Maxson, unpublished obser-
vations). These cells can be transfected efficiently, both with
plasmid constructs as well as RNAi, and can be used for
chromatin immunoprecipitation assays. We conclude that
the O9-1 multipotent cranial neural crest cell line will serve
FIG. 5. CD44 marks a subset of migratory and post-migratory cranial neural crest cells in E8.75 mouse embryos. (A–H)
Sections of cranial region of E8.75 mouse embryo carrying the Wnt1-Cre; R26R-GFP reporter. Migratory as well as post-
migratory neural crest cells are labeled by GFP in this system (green signal in B and F). (C, D, G, H) Immunostaining reveals
that a subset of cranial neural crest expresses CD44 (yellow signal in D andH, arrows). Panels (B) and (F) show the boxed area
in (A) and (E). Note that not all of the migratory neural crest cells are positive for CD44 (arrowhead in B). ne, neural ectoderm;
pa, first pharyngeal arch. Scale bars: in (D), 50 mm for (B–D); in (H), 50mm for (F–H); in (E), 100 mm for (A, E).
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as a useful tool for the investigation of the biochemical
mechanisms of cranial neural crest development.
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